Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. However, there are a few important safeguards that must be put into place before these “similar but not the same” versions of biologics can be safely introduced to the public. Join Dr.